Gouda MA - Search Results

1

The evolving landscape of tissue-agnostic therapies in precision oncology.

Subbiah V, Gouda MA, Ryll B, Burris HA 3rd, Kurzrock R. Subbiah V, et al. Among authors: gouda ma. CA Cancer J Clin. 2024 Sep-Oct;74(5):433-452. doi: 10.3322/caac.21844. Epub 2024 May 30. CA Cancer J Clin. 2024. PMID: 38814103 Free article. Review.

2

Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers.

Gouda MA, Huang HJ, Piha-Paul SA, Call SG, Karp DD, Fu S, Naing A, Subbiah V, Pant S, Dustin DJ, Tsimberidou AM, Hong DS, Rodon J, Meric-Bernstam F, Janku F. Gouda MA, et al. JCO Precis Oncol. 2022 Jul;6:e2100512. doi: 10.1200/PO.21.00512. JCO Precis Oncol. 2022. PMID: 35834760 Free PMC article.

3

Precision oncology for biliary tract tumors: it's written in blood!

Gouda MA, Subbiah V. Gouda MA, et al. Ann Oncol. 2022 Dec;33(12):1209-1211. doi: 10.1016/j.annonc.2022.09.157. Epub 2022 Sep 28. Ann Oncol. 2022. PMID: 36182024 Free article. No abstract available.

4

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy.

Gouda MA, Subbiah V. Gouda MA, et al. ESMO Open. 2023 Apr;8(2):100788. doi: 10.1016/j.esmoop.2023.100788. Epub 2023 Feb 24. ESMO Open. 2023. PMID: 36842301 Free PMC article. Review.

5

Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.

Gouda MA, Nelson BE, Buschhorn L, Wahida A, Subbiah V. Gouda MA, et al. Clin Cancer Res. 2023 Aug 1;29(15):2753-2760. doi: 10.1158/1078-0432.CCR-23-0090. Clin Cancer Res. 2023. PMID: 37061987 Free PMC article.

6

N-of-1 Trials in Cancer Drug Development.

Gouda MA, Buschhorn L, Schneeweiss A, Wahida A, Subbiah V. Gouda MA, et al. Cancer Discov. 2023 Jun 2;13(6):1301-1309. doi: 10.1158/2159-8290.CD-22-1377. Cancer Discov. 2023. PMID: 37070849 Free PMC article. Review.

7

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors.

Gouda MA, Subbiah V. Gouda MA, et al. Am Soc Clin Oncol Educ Book. 2023 May;43:e404770. doi: 10.1200/EDBK_404770. Am Soc Clin Oncol Educ Book. 2023. PMID: 37159870 Free article. Review.

8

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma.

Nelson BE, Reddy NK, Huse JT, Amini B, Nardo M, Gouda M, Weathers SP, Subbiah V. Nelson BE, et al. NPJ Precis Oncol. 2023 May 25;7(1):47. doi: 10.1038/s41698-023-00398-5. NPJ Precis Oncol. 2023. PMID: 37231247 Free PMC article.

9

The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications.

Denu RA, Moyers JT, Gouda MA, Conley AP, Lazar AJ, Subbiah V. Denu RA, et al. Among authors: gouda ma. Clin Cancer Res. 2023 Nov 14;29(22):4669-4678. doi: 10.1158/1078-0432.CCR-23-0876. Clin Cancer Res. 2023. PMID: 37643131

10

ALK fusions in the pan-cancer setting: another tumor-agnostic target?

Shreenivas A, Janku F, Gouda MA, Chen HZ, George B, Kato S, Kurzrock R. Shreenivas A, et al. Among authors: gouda ma. NPJ Precis Oncol. 2023 Sep 29;7(1):101. doi: 10.1038/s41698-023-00449-x. NPJ Precis Oncol. 2023. PMID: 37773318 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

77 results

Search Page

Filters